<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Savient Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/savient-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AEM) Company News for November 4, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/11/04/aem-company-news-for-november-4-2011-corporate-summary/86532</link>
		<comments>http://www.stockbloghub.com/2011/11/04/aem-company-news-for-november-4-2011-corporate-summary/86532#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:38:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Gold]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[AEM]]></category>
		<category><![CDATA[Agnico-Eagle Mines Limited]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[Directv Group Inc]]></category>
		<category><![CDATA[DTV]]></category>
		<category><![CDATA[EL]]></category>
		<category><![CDATA[Elizabeth Arden Inc.]]></category>
		<category><![CDATA[Energizer Holdings Inc.]]></category>
		<category><![CDATA[ENR]]></category>
		<category><![CDATA[Estee Lauder Companies Inc.]]></category>
		<category><![CDATA[PCG]]></category>
		<category><![CDATA[PG & E Corporation]]></category>
		<category><![CDATA[RDEN]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86532</guid>
		<description><![CDATA[•    Allos Therapeutics (NASDAQ:ALTH) posted a Q3 loss of $0.11 per share, lower than the Zacks Consensus Estimate for a loss of $0.15 per share. Revenues for the quarter rose 73.2% year-over-year to $14.2 million, surpassing the Zacks Consensus Estimate of $13.0 million •    Elizabeth Arden (NASDAQ:RDEN) reported Q1 EPS of $0.31, exceeding the Zacks Consensus Estimate of $0.29 per share. Revenues for the quarter rose 6.6% year-over-year to $303.5 million, marginally higher than the Zacks Consensus Estimate of $303.0 million •    Savient Pharmaceuticals (NASDAQ:SVNT) posted a Q3 loss of $0.39 per share, narrower than the Zacks Consensus Estimate for a loss of $0.43 per share. Revenues for the quarter rose 19.7% year-over-year to $2.04 billion •    Energizer (NYSE:ENR) reported Q4 EPS of $1.10, ex-items, lower than the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/aem-company-news-for-november-4-2011-corporate-summary/86532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDEA) Ardea Biosciences Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247</link>
		<comments>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:38:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48247</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (RDEA) with a target price of $20. Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV) and cancer. Ardea recently reported disappointing second quarter 2010 results. The development stage biopharmaceutical company’s second-quarter 2010 net loss of $12.8 million, or $0.57 per share was wider than the year-ago loss of $8 million, or $0.44 per share and the Zacks Consensus Estimate of a loss at $0.46. The wider loss at Ardea in the reported quarter was due to the increased amount spent on developing its pipeline coupled with lower revenues in the quarter. Revenue in the reported quarter slipped 36% to $3.5 million. We are pleased with Ardea’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/rdea-ardea-biosciences-analyst-maintains-neutral-rating/48247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SVNT) Savient Pharmaceuticals Announces the FDA accepted Biologics License Application</title>
		<link>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529</link>
		<comments>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529#comments</comments>
		<pubDate>Thu, 01 Apr 2010 15:02:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32529</guid>
		<description><![CDATA[Recently, Savient Pharmaceuticals, Inc. (SVNT) announced that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its gout candidate, Krystexxa (pegloticase). The BLA was resubmitted by Savient on March 15, 2010. A response from the FDA should be out in the fourth quarter of 2010 (target date: Sept 14, 2010). As a reminder, the FDA issued a complete response letter [CRL] in July 2009 whereby the agency refused to approve the BLA for Krystexxa because Savient changed the way the drug was manufactured, among other issues. The resubmission is classified by the FDA as a Class 2 review. The resubmitted application is inclusive of additional chemistry, manufacturing and controls, Safety Update, Labeling, Risk Evaluation and Mitigation Strategy, and Medication Guide, as requested in the complete ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/svnt-savient-pharmaceuticals-announces-the-fda-accepted-biologics-license-application/32529/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SVNT) Savient Pharmaceuticals Gout Drug Trials Suspended</title>
		<link>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566</link>
		<comments>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:14:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences Inc.]]></category>
		<category><![CDATA[RDEA]]></category>
		<category><![CDATA[Savient Pharmaceuticals Inc]]></category>
		<category><![CDATA[SVNT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15566</guid>
		<description><![CDATA[Savient Pharmaceuticals Inc. (SVNT), after meeting officials from the U.S. Food and Drug Administration (FDA) on Monday, announced that the agency does not expect further clinical trials to be conducted for its gout drug Krystexxa, as the company has now reverted to its original manufacturing process for producing phase III trial material for Krystexxa. The meeting discussed the Complete Response Letter (CRL) received on July 31, 2009 from the FDA, whereby the agency refused to approve the Biologics License Application (BLA) for Krystexxa (pegloticase) because Savient changed the way the drug was manufactured, among other issues. As a result of this ruling, Savient stated that it can meet its previously announced timeline of filing the resubmission in response to the CRL in early 2010 .The resubmission will be classified as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/rdea-savient-pharmaceuticals-gout-drug-trials-suspended/15566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

